Ambalal Sarabhai Enterprises Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ambalal Sarabhai Enterprises Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹16 of operating cash. Lower than 89% of Healthcare companies in India.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 14% of its market value (net debt). Lower than 85% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹16Over the last 3 years, every ₹100 of reported profit came with ₹16 of operating cash.
Lower than 89% of Healthcare companies in India.
Self-Funding Ratio
0.4×Over the last 3 years its own operating cash paid for 40% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 84% of Healthcare companies in India.
Cash Locked Ratio
₹8For every ₹100 of sales, ₹8 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹7 from others' credit three years earlier.
Less money tied up than 75% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹20Sales grew 18% in 3 years; of every extra ₹100 of sales, ₹20 became extra profit.
Higher than 61% of Healthcare companies in India.
Asset Productivity Ratio
+18% / +14%In 3 years sales changed by +18% while total assets changed by +14%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
0.4×Debt due within a year is covered 0.4 times by its yearly operating cash.
Lower than 76% of Healthcare companies in India.
Cash Cushion Ratio
−14%Debt, after subtracting cash, equals 14% of its market value (net debt).
Lower than 85% of Healthcare companies in India.
Tangible Assets Ratio
91%Of every ₹100 the company owns, ₹91 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 69% of Healthcare companies in India.
Tangible Net Worth Ratio
83%Of every ₹100 of net worth, ₹83 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 70% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Ambalal Sarabhai Enterprises Limited owes ₹0.44 for every ₹1 it owns. Net profit rose 261% in the year to Mar 2026, and grew 16% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
20.4Investors pay ₹20.4 for every ₹1 of Ambalal Sarabhai Enterprises Limited's yearly profit, lower than 82% of Healthcare companies in India.
P/B ratio
1.68The share price is 1.68 times Ambalal Sarabhai Enterprises Limited's book value per share, lower than 90% of Healthcare companies in India.
Market cap
₹266 CrThe total market value of all of Ambalal Sarabhai Enterprises Limited's shares at today's price (share price × number of shares), smaller than 91% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹158 CrWhat Ambalal Sarabhai Enterprises Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹20.66Net worth divided by the number of shares. The share price of ₹34.65 is 1.7 times this, which is the P/B above.
Return on equity (ROE)
8.2%Ambalal Sarabhai Enterprises Limited earned 8.2% on its shareholders' money over the last year, lower than 74% of Healthcare companies in India.
Owes vs Owns
0.44×Ambalal Sarabhai Enterprises Limited owes ₹0.44 for every ₹1 it owns (low), higher than 68% of Healthcare companies in India.
Dividend yield
NoneAmbalal Sarabhai Enterprises Limited does not currently pay a dividend.
Revenue growth
+3%Revenue rose 3% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Profit growth
+261%Net profit rose 261% in the year to Mar 2026, and grew 16% a year on average over 3 years.
Profit margin
8.9%Ambalal Sarabhai Enterprises Limited keeps ₹9 of every ₹100 of revenue as net profit.
Cash quality
0.8×Cash from Ambalal Sarabhai Enterprises Limited's business was 0.8× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
4.0×Ambalal Sarabhai Enterprises Limited's operating profit covered its interest costs 4.0 times in the year to Mar 2026.
Cash vs debt
Net debtAmbalal Sarabhai Enterprises Limited had ₹40 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Ambalal Sarabhai Enterprises Limited's P/E ratio?
Investors pay ₹20.4 for every ₹1 of Ambalal Sarabhai Enterprises Limited's yearly profit, lower than 82% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Ambalal Sarabhai Enterprises Limited: ₹266 Cr ÷ ₹158 Cr (31 Mar 2026) = 1.7.
What is Ambalal Sarabhai Enterprises Limited's return on equity?
Ambalal Sarabhai Enterprises Limited earned 8.2% on its shareholders' money over the last year, lower than 74% of Healthcare companies in India.
How much does Ambalal Sarabhai Enterprises Limited owe compared with what it owns?
Ambalal Sarabhai Enterprises Limited owes ₹0.44 for every ₹1 it owns (low), higher than 68% of Healthcare companies in India.
Does Ambalal Sarabhai Enterprises Limited pay a dividend?
No. Ambalal Sarabhai Enterprises Limited does not currently pay a dividend.
Is Ambalal Sarabhai Enterprises Limited's revenue growing?
Revenue rose 3% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.